
NeuroPace (NPCE) Stock Forecast & Price Target
NeuroPace (NPCE) Analyst Ratings
Bulls say
NeuroPace Inc. reported a notable improvement in gross margin, with figures rising to 73.6% in 1Q24 from 71.7% in 1Q23, attributed to enhanced manufacturing efficiencies and increased sales of the RNS System. The company experienced robust revenue growth of approximately 41% year-over-year, achieving total revenue of $18.0 million, primarily driven by the heightened adoption of the RNS System despite a slight decline in replacement implant revenue. Looking ahead, NeuroPace anticipates continued strong performance in the second half of the year, supported by enhanced utilization in Level 4 centers and broader community engagement initiatives.
Bears say
NeuroPace Inc. continues to face significant financial challenges, highlighted by a historical record of net losses, which raises concerns about its long-term viability and growth prospects. The company heavily relies on a limited number of suppliers, making it vulnerable to supply chain disruptions and price volatility that could negatively impact its financial condition. Additionally, potential liabilities from data privacy issues pose further risks to the business, further complicating its path to sustainable profitability.
This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.
NeuroPace (NPCE) Analyst Forecast & Price Prediction
Start investing in NeuroPace (NPCE)
Order type
Buy in
Order amount
Est. shares
0 shares